US 12,076,331 B2
Inositol derivatives for use in pathological crystallization
Anna Kletzmayr, Zürich (CH); Makoto Kuro-o, St. Gallen (CH); Hirosaka Hayashi, St. Gallen (CH); Mattias Ivarsson, St. Gallen (CH); and Jean-Christophe Leroux, Zürich (CH)
Assigned to ETH Zurich, Zurich (CH); and Universitat Bern, Bern (CH)
Filed by ETH Zurich, Zurich (CH); and Universitat Bern, Bern (CH)
Filed on Jun. 12, 2023, as Appl. No. 18/332,849.
Application 18/332,849 is a continuation of application No. 17/340,163, filed on Jun. 7, 2021, granted, now 11,707,470.
Application 17/340,163 is a continuation in part of application No. 16/852,587, filed on Apr. 20, 2020, granted, now 11,028,112, issued on Jun. 8, 2021.
Application 16/852,587 is a continuation in part of application No. 16/060,980, granted, now 10,624,909, issued on Apr. 21, 2020, previously published as PCT/EP2016/080657, filed on Dec. 12, 2016.
Claims priority of application No. 15199682 (EP), filed on Dec. 11, 2015; application No. 16164299 (EP), filed on Apr. 7, 2016; application No. 16173422 (EP), filed on Jun. 7, 2016; and application No. 20209090 (EP), filed on Nov. 20, 2020.
Prior Publication US 2023/0338401 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/6615 (2006.01); A61P 13/04 (2006.01)
CPC A61K 31/6615 (2013.01) [A61P 13/04 (2018.01)] 4 Claims
 
1. A pharmaceutical composition comprising a compound having the formula

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.